Blood test holds key to treating prostate cancer
A simple blood test could help doctors devise personalised treatments for men with advanced prostate cancer.
The new cheap test can predict which patients are likely to respond to new targeted drugs, and who might be better served by alternative therapies.
It looks for multiple copies of a gene for the androgen receptor, a hormone-sensitive molecule that helps many prostate cancers to grow.
Men with multiple copies of the gene respond much less well to the drugs abiraterone and enzalutamide, both used to treat advanced prostate cancer.
Currently, there is no approved test to help doctors choose the best treatments for an individual.